Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
15.06
+1.32 (9.61%)
At close: Aug 26, 2026, 4:00 PM EDT
14.25
-0.81 (-5.38%)
Pre-market: Aug 27, 2026, 7:19 AM EDT
Adlai Nortye Employees
Adlai Nortye had 109 employees as of December 31, 2025. The number of employees decreased by 14 or -11.38% compared to the previous year.
Employees
109
Change (1Y)
-14
Growth (1Y)
-11.38%
Revenue / Employee
$165,651
Profits / Employee
-$206,688
Market Cap
969.83M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 109 | -14 | -11.38% |
| Dec 31, 2024 | 123 | -4 | -3.15% |
| Dec 31, 2023 | 127 | -2 | -1.55% |
| Jun 30, 2023 | 130 | - | - |
| Mar 31, 2023 | 129 | - | - |
| Dec 31, 2022 | 129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Olema Pharmaceuticals | 150 |
| Cybin | 100 |
| Annexon | 92 |
| Theravance Biopharma | 90 |
| SpyGlass Pharma | 76 |
| Aclaris Therapeutics | 73 |
| Design Therapeutics | 55 |
ANL News
- 12 days ago - Adlai Nortye Earnings release: Q2 2026 - Filings
- 13 days ago - Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress - GlobeNewsWire
- 24 days ago - Adlai Nortye submits clinical trial notification to Australia TGA for AN4035 - TheFly
- 24 days ago - Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia - GlobeNewsWire
- 6 weeks ago - Adlai Nortye doses first patient in AN9025 trial - TheFly
- 6 weeks ago - Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 - GlobeNewsWire
- 6 weeks ago - Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists - GlobeNewsWire
- 2 months ago - Cantor starts Adlai Nortye at Overweight, sees 180% upside - TheFly